BioCentury
ARTICLE | Politics & Policy

Vote delayed on House patent bill

July 17, 2015 1:31 AM UTC

Controversy over the biopharma industry's efforts to gain exemption from inter partes review (IPR) of granted patents, as well as disputes over other provisions, will delay a vote by the U.S. House of Representatives on the Innovation Act (H.R. 9), a patent reform bill. The vote, originally slated for this month, will be delayed until September at the earliest.

The Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA) have convinced a number of lawmakers to support their demands for excluding drug patents from the IPR process (see BioCentury, May 18). ...